<DOC>
	<DOCNO>NCT00114959</DOCNO>
	<brief_summary>This open label , multi-center study 77 patient CML chronic , accelerate blast phase develop resistance fail previous treatment Gleevec ( imatinib mesylate ) . Because patient may still sensitive Gleevec , add Homoharringtonine may restore response Gleevec combine treatment may promote good response use Gleevec alone .</brief_summary>
	<brief_title>Homoharringtonine With Oral Gleevec Chronic , Accelerated Blast Phase Chronic Myeloid Leukemia ( CML )</brief_title>
	<detailed_description>Every 4 week , study medicine Homoharringtonine give vein daily 5 day along continue daily dos approve medicine Gleevec take mouth . The safety effectiveness combine treatment CML patient study . Patients achieve meaningful hematologic cytogenetic response 4 cycle less discontinue . Otherwise , patient may continue additional cycle combine treatment maximum 12 cycle .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Homoharringtonine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Harringtonines</mesh_term>
	<criteria>Male female patient 16 year old Philadelphia chromosome ( Ph ) positive chronic myelogenous leukemia ( CML ) either chronic , accelerate blast phase Patients chronic phase CML either refractory ( failed achieve hematologic cytogenetic response ) resistant ( respond initially subsequently lose hematologic cytogenetic response ) prior imatinib mesylate therapy . Failure achieve cytogenetic response define follow : cytogenetic response 3 month therapy imatinib mesylate , major cytogenetic response 12 month therapy , loss complete cytogenetic response document twice , loss major cytogenetic response least . Patients accelerate blast phase may newly diagnose previously untreated previously treat imatinib mesylate , refractory resistant agent fail achieve least complete hematologic cytogenetic response treatment , previously define . Patients accelerate phase meet one follow criterion : great equal 15 % le 30 % blast peripheral blood bone marrow , great equal 30 % blast + promyelocytes peripheral blood bone marrow , great equal 20 % basophils peripheral blood , platelet count le 100*10^9/L unrelated therapy clonal evolution . CML blast phase define great equal 30 % blast bone marrow presence extramedullary disease Patients must complete previous antileukemic therapy least 2 week , except note , fully recover side effect previous therapy , unless disease progression necessitate early therapy . Patients may receive leukapheresis , hydroxyurea anagrelide 24 hour prior start study treatment . Patients receive imatinib mesylate may continue receive uninterrupted , except 3day window treatment cycle 1 . Bilirubin le equal 2 time upper limit normal ( ULN ) ; alanine aminotransferase ( ALT ) less equal 3 time ULN ; creatinine le equal 1.5 time ULN Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Be able comply requirement entire study Be able willing provide write informed consent prior study related procedure Patients partner must use effective contraceptive study dose period . The following consider effective contraceptive : oral contraceptive pill , condom , diaphragm plus spermicide , abstinence , patient partner surgically sterile , patient partner 2 year postmenopausal , injectable implantable agent/device . New York Heart Association ( NYHA ) Class III IV heart disease , active ischemia uncontrolled cardiac condition angina pectoris , clinically significant cardiac arrhythmia require therapy , uncontrolled hypertension congestive heart failure Myocardial infarction previous 12 week Other intercurrent illness would preclude study conduct assessment , include limited another active malignancy , uncontrolled active infection , positive human immunodeficiency virus ( HIV ) human Tcell lymphotropic virus ( HTLV ) I/II status Pregnant lactate Any medical psychiatric condition may compromise ability give write informed consent comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>ChemGenex Pharmaceuticals , Ltd</keyword>
	<keyword>ChemGenex Pharmaceuticals</keyword>
	<keyword>ChemGenex</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Myeloid Leukemia , Chronic</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Myeloid Leukemia</keyword>
	<keyword>Chronic Phase</keyword>
	<keyword>Accelerated Phase</keyword>
	<keyword>Blast Phase</keyword>
	<keyword>Myeloid , Leukemia , Chronic , Accelerated Phase</keyword>
	<keyword>Myeloid , Leukemia , Chronic</keyword>
	<keyword>Leukemia , Myeloid , Chronic</keyword>
	<keyword>Leukemia , Myeloid , Chronic-Phase</keyword>
	<keyword>Leukemia , Myeloid , Chronic Phase</keyword>
	<keyword>Leukemia , Myeloid , Accelerated-Phase</keyword>
	<keyword>Myeloid , Leukemia , Chronic , Chronic Phase</keyword>
	<keyword>Leukemia , Myeloid , Accelerated Phase</keyword>
	<keyword>Homoharringtonine</keyword>
	<keyword>Omacetaxine</keyword>
</DOC>